FindTrial
Sign In

Evaluation of Cerebral Small Vessel Disease in Patient With Primary Aldosteronism

Evaluation of Cerebral Small Vessel Disease in Patient With Primary Aldosteronism

Status
UNKNOWN
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03821571
Enrollment
60
Registered
2019-01-30
Start date
2019-01-25
Completion date
2020-12-31
Last updated
2019-01-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Evaluation of Cerebral Small Vessel Disease in Patient With Primary Aldosteronism

Keywords

Hypertension,primary aldosteronism

Brief summary

Hypertension is known to be the major risk factor for stroke. The most common cause of secondary hypertension, primary aldosteronism (PA), is characterized by the excessive secretion of aldosterone and is related to hypertension and hypokalemia. PA accounts for 3-10 % of hypertensive patients, and a higher incidence of vascular complications compared to patients with essential hypertension was observed in several studies. The vascular injury from excessive aldosterone can occur via oxidative stress and collagen remodeling, causing endothelial dysfunction and fibrosis in the vasculature. The association between cerebral small vessel disease (cSVD) and hypertension has been well studies in the past decades. However, not much study has focused on the cSVD burden in patient with PA. The goal of this study is to understand the features of cSVD in patients with PA and for the purpose of understanding the underlying pathophysiology of cerebrovascular injury in this particular patient group.

Interventions

DIAGNOSTIC_TESTBrain MRI

Brain MRI with blood sensitive sequence (SWI) will be performed to all enrolled patients.

Sponsors

National Taiwan University Hospital
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to 90 Years
Healthy volunteers
Yes

Inclusion criteria

* age between 20-90 years-old * patient with primary aldosteronism or healthy control * consciousness clear * willing to receive brain MRI

Exclusion criteria

* renal failure or Creatinine \> 2mg/dl * coagulopathy or hepatic insufficiency * unstable vital sign under inotropic agents * pregnancy * metal implant or cardiac pacemaker * major brain surgery

Design outcomes

Primary

MeasureTime frameDescription
Cerebrovascular reactivityDuring the brain MRICerebrovascular reactivity measured by MRI under primary aldosteronism

Countries

Taiwan

Contacts

Primary ContactHsin-Hsi Tsai
tsaihsinhsi@gmail.com+886 939916897
Backup ContactBo-Ching Lee, MD
bochinglee@gmail.com+886 972653442

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026